Table 2.
The relationship between the level of LP-PLA2 and seriousness of clinical Presentation
| Group | Control | SA | UA | AMI | P |
|---|---|---|---|---|---|
| N | 294 | 192 | 330 | 240 | |
| Age (years) | 60.63 ± 11.96 | 66.00 ± 13.66 | 64.80 ± 10.99 | 62.05 ± 11.58 | 0.130 |
| Male(%) | 204 (69.4) | 150 (78.1) | 252 (76.4) | 186 (77.5) | 0.762 |
| Smoking(%) | 84 (28.6) | 66 (34.3) | 138 (41.8) | 108 (45) | 0.362 |
| Hypertension(%) | 168 (57.1) | 120 (62.5) | 252 (76.4) | 120 (50) | 0.051 |
| Diabetes (%) | 54 (18.4) | 60 (31.2) | 84 (25.5) | 72 (30) | 0.514 |
| FBG (mmol/L)a | 5.35 (4.39–8.56) | 6.13 (4.69–10.36) | 6.14 (4.72–10.38) | 6.23 (4.56–10.42) | 0.071 |
| Lp(a) (mmol/L)a | 230.39 (112.06–428.32) | 282.16 (115.22–652.36) | 308.20 (122.08–721.12) | 322.03 (130.06–732.16) | 0.390 |
| TC (mmol/L) | 4.40 ± 1.13 | 4.25 ± 1.13 | 4.31 ± 1.19 | 4.53 ± 1.15 | 0.724 |
| TG (mmol/L) | 1.52 ± 0.97 | 1.65 ± 0.96 | 1.64 ± 0.96 | 1.65 ± 0.69 | 0.782 |
| LDL-C (mmol/L) | 2.82 ± 0.93 | 2.65 ± 0.89 | 2.65 ± 1.02 | 2.94 ± 0.88 | 0.432 |
| HDL-C (mmol/L) | 1.17 ± 0.28 | 1.11 ± 0.22 | 1.05 ± 0.27* | 1.04 ± 0.24* | 0.056 |
| Lp-PLA2(ng/ml) a | 172.83 (92.35–296.42) | 193.84 (102.35–372.35) | 263.95 (172.32–396.45)*& | 311.45 (185.24–412.35)*& | < 0.001 |
aindicated median and inter-quartile range, *P < 0.05 versus control group, &P < 0.05 versus SA group